Printer Friendly

IMMUNOMEDICS PRESENTS CANCER THERAPEUTICS AT THE AMERICAN COLLEGE OF NUCLEAR PHYSICIANS IN SAN DIEGO

 IMMUNOMEDICS PRESENTS CANCER THERAPEUTICS
 AT THE AMERICAN COLLEGE OF NUCLEAR PHYSICIANS IN SAN DIEGO
 WARREN, N.J., March 4 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) today presented at the American College of Nuclear Physicians meeting in San Diego the company's cancer therapeutics, currently in preclinical testing, involving the use of monoclonal antibodies directly labeled with rhenium-188 and the use of cytokines in combination with radioimmunotherapy.
 In his invited lecture, Immunomedics' Chairman, David M. Goldenberg, stated, "There are excellent prospects for advances in cancer therapy with new generations of recombinantly engineered monoclonal antibodies bearing high concentrations of the deep-penetrating radioisotope, rhenium-188, that can treat cancer while sparing normal tissues. In animal studies, antibodies labeled with rhenium-188 showed excellent tumor targeting and tumor growth retardation." The company plans to enter its first patient in Phase I/II clinical trials using rhenium-188 by the end of 1992.
 "Immunomedics' new method of cancer treatment combining radioimmunotherapy with certain cytokines has shown positive results in animal experiments protecting healthy cells, particularly in the bone marrow, allowing up to 25 percent higher doses to be used. This method may reduce toxicity to blood-forming cells of the bone marrow, offsetting the adverse effects of radioimmunotherapy or chemotherapy," further stated Goldenberg.
 Goldenberg also discussed the initial patient results using Immunomedics' lymphoma therapy product, ImmuRAIT(TM)-LL2. In eight patients enrolled at the Garden State Cancer Center in Newark, N.J., there was one complete response and two partial responses using ImmuRAIT-LL2.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections.
 -0- 3/4/92
 /CONTACT: Amy Factor of Immunomedics, 908-647-5400/
 (IMMU) CO: Immunomedics, Inc. ST: New Jersey, California IN: MTC SU:


SH-OS -- NY064 -- 5017 03/04/92 14:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 4, 1992
Words:324
Previous Article:JURY INVALIDATES ORMCO PATENT FOR BIOMERICA SUBSIDIARY LANCER ORTHODONTICS
Next Article:AMERICAN FOREST COUNCIL RESPONDS TO THREATENED LAWSUITS AGAINST PRIVATE LANDOWNERS
Topics:


Related Articles
IMMUNOMEDICS AWARDED PATENT FOR IMAGING AND THERAPEUTIC AGENTS
IMMUNOMEDICS REPORT NEW RESULTS OF LUNG CANCER AND LYMPHOMA IMAGING AGENTS
POTENTIAL NEW CANCER THERAPEUTIC DEVELOPED BY IMMUNOMEDICS AND NATIONAL CANCER INSTITUTE TEAM; RESULTS PRESENTED AT CANCER MEETING
IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS OF A NEW CANCER THERAPEUTIC; ANTIBODY HUMANIZATION PROGRAM ALSO ADVANCES
IMMUNOMEDICS' COLORECTAL CANCER DETECTION AGENT ACCLAIMED AT SURGICAL CONGRESS: FINDINGS SHOW ACCURACY OF OVER 90 PERCENT
IMMUNOMEDICS REPORTS RESULTS WITH INFECTIOUS DISEASE IMAGING AGENT
IMMUNOMEDICS REPORTS ON REPEAT USAGEOF COLORECTAL CANCER DETECTION AGENT
IMMUNOMEDICS REPORTS ON POTENTIAL DIAGNOSTIC FOR AIDS-RELATED PNEUMONIA
Immunomedics Reports on New Drug Candidate at Cancer Conference.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters